

Bonaventura Clotet

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11902168/publications.pdf>

Version: 2024-02-01

411
papers

27,160
citations

6254

80
h-index

8866

145
g-index

428
all docs

428
docs citations

428
times ranked

19693
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection. Cell Reports Medicine, 2022, 3, 100523.	6.5	18
2	HIV-1 trans-Infection Mediated by DCs: The Tip of the Iceberg of Cell-to-Cell Viral Transmission. Pathogens, 2022, 11, 39.	2.8	4
3	Gut microbiome signatures linked to HIV-1 reservoir size and viremia control. Microbiome, 2022, 10, 59.	11.1	19
4	Heterogeneous Infectivity and Pathogenesis of SARS-CoV-2 Variants Beta, Delta and Omicron in Transgenic K18-hACE2 and Wildtype Mice. Frontiers in Microbiology, 2022, 13, .	3.5	39
5	Performance of SARS-CoV-2 Antigen-Detecting Rapid Diagnostic Tests for Omicron and Other Variants of Concern. Frontiers in Microbiology, 2022, 13, .	3.5	15
6	Virological and Clinical Determinants of the Magnitude of Humoral Responses to SARS-CoV-2 in Mild-Symptomatic Individuals. Frontiers in Immunology, 2022, 13, 860215.	4.8	6
7	Hydroxychloroquine for Early Treatment of Adults With Mild Coronavirus Disease 2019: A Randomized, Controlled Trial. Clinical Infectious Diseases, 2021, 73, e4073-e4081.	5.8	219
8	A Specific Mobile Health Application for Older HIV-Infected Patients: Usability and Patient's Satisfaction. Telemedicine Journal and E-Health, 2021, 27, 432-440.	2.8	17
9	Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity. Biochemical and Biophysical Research Communications, 2021, 538, 187-191.	2.1	86
10	Hydroxychloroquine pre-exposure prophylaxis for COVID-19 in healthcare workers. Journal of Antimicrobial Chemotherapy, 2021, 76, 827-829.	3.0	7
11	A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19. New England Journal of Medicine, 2021, 384, 417-427.	27.0	179
12	Dissemination of <i>Mycobacterium tuberculosis</i> is associated to a <i>SIGLEC1</i> null variant that limits antigen exchange via trafficking extracellular vesicles. Journal of Extracellular Vesicles, 2021, 10, e12046.	12.2	9
13	Incidence of Recurrent High-Grade Anal Dysplasia in HIV-1-Infected Men and Women Following Infrared Coagulation Ablation: A Retrospective Cohort Study. Pathogens, 2021, 10, 208.	2.8	2
14	Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study. Lancet Infectious Diseases, The, 2021, 21, 629-636.	9.1	303
15	Analytical and clinical performance of the panbio COVID-19 antigen-detecting rapid diagnostic test. Journal of Infection, 2021, 82, 186-230.	3.3	73
16	Performance characteristics of five antigen-detecting rapid diagnostic test (Ag-RDT) for SARS-CoV-2 asymptomatic infection: a head-to-head benchmark comparison. Journal of Infection, 2021, 82, 269-275.	3.3	42
17	Monitoring Natural SARS-CoV-2 Infection in Lions (Panthera leo) at the Barcelona Zoo: Viral Dynamics and Host Responses. Viruses, 2021, 13, 1683.	3.3	51
18	Single nucleotide polymorphisms in PNPLA3, ADAR-1 and IFIH1 are associated with advanced liver fibrosis in patients co-infected with HIV-1//hepatitis C virus. Aids, 2021, 35, 2497-2502.	2.2	6

#	ARTICLE	IF	CITATIONS
19	Same-day SARS-CoV-2 antigen test screening in an indoor mass-gathering live music event: a randomised controlled trial. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1365-1372.	9.1	73
20	Accentuated aging associated with HIV in a Mediterranean setting occurs mainly in persons aged >70 years: a comparative cohort study (Over50 cohort). <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021, , 1-8.	1.2	1
21	First Detection of SARS-CoV-2 Delta (B.1.617.2) Variant of Concern in a Dog with Clinical Signs in Spain. <i>Viruses</i> , 2021, 13, 2526.	3.3	20
22	Routine Screening of Anal Cytology in Persons With Human Immunodeficiency Virus and the Impact on Invasive Anal Cancer: A Prospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2020, 71, 390-399.	5.8	38
23	TL1Aâ€“DR3 Plasma Levels Are Predictive of HIV-1 Disease Control, and DR3 Costimulation Boosts HIV-1â€“Specific T Cell Responses. <i>Journal of Immunology</i> , 2020, 205, 3348-3357.	0.8	3
24	A randomized pilot trial to evaluate the benefit of the concomitant use of atorvastatin and Raltegravir on immunological markers in protease-inhibitor-treated subjects living with HIV. <i>PLoS ONE</i> , 2020, 15, e0238575.	2.5	3
25	Detection of SARS-CoV-2 in a cat owned by a COVID-19â€“affected patient in Spain. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 24790-24793.	7.1	154
26	HIV-1 Gag mutations alone are sufficient to reduce darunavir susceptibility during virological failure to boosted PI therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2535-2546.	3.0	7
27	Pharmacological Modulation of SAMHD1 Activity by CDK4/6 Inhibitors Improves Anticancer Therapy. <i>Cancers</i> , 2020, 12, 713.	3.7	14
28	In vivo Effects of Romidepsin on T-Cell Activation, Apoptosis and Function in the BCN02 HIV-1 Kick&Kill Clinical Trial. <i>Frontiers in Immunology</i> , 2020, 11, 418.	4.8	23
29	HIVconsv Vaccines and Romidepsin in Early-Treated HIV-1-Infected Individuals: Safety, Immunogenicity and Effect on the Viral Reservoir (Study BCN02). <i>Frontiers in Immunology</i> , 2020, 11, 823.	4.8	55
30	Immediate Versus Deferred Switching From a Boosted Protease Inhibitorâ€“based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age â‰¥50 Years: Final 96-Week Results of the NEAT022 Study. <i>Clinical Infectious Diseases</i> , 2019, 68, 597-606.	5.8	34
31	Therapeutic Vaccination Refocuses T-cell Responses Towards Conserved Regions of HIV-1 in Early Treated Individuals (BCN 01 study). <i>EClinicalMedicine</i> , 2019, 11, 65-80.	7.1	52
32	Natural History of Anal Squamous Intraepithelial Lesions in HIV-Positive Men with Normal Baseline Cytology. <i>AIDS Patient Care and STDs</i> , 2019, 33, 459-465.	2.5	8
33	Re-boost immunizations with the peptide-based therapeutic HIV vaccine, Vacc-4x, restores geometric mean viral load set-point during treatment interruption. <i>PLoS ONE</i> , 2019, 14, e0210965.	2.5	8
34	Dual effect of the broad spectrum kinase inhibitor midostaurin in acute and latent HIV-1 infection. <i>Antiviral Research</i> , 2019, 168, 18-27.	4.1	8
35	Evolution of the gut microbiome following acute HIV-1 infection. <i>Microbiome</i> , 2019, 7, 73.	11.1	69
36	HIV-1 envelope glycoproteins isolated from Viremic Non-Progressor individuals are fully functional and cytopathic. <i>Scientific Reports</i> , 2019, 9, 5544.	3.3	17

#	ARTICLE	IF	CITATIONS
37	Simplification of Antiretroviral Treatment from Darunavir/Ritonavir Monotherapy to Darunavir/Cobicistat Monotherapy: Effectiveness and Safety in Routine Clinical Practice. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 513-518.	1.1	20
38	Low nadir CD4+ T-cell counts predict gut dysbiosis in HIV-1 infection. <i>Mucosal Immunology</i> , 2019, 12, 232-246.	6.0	56
39	Costa "effectiveness of initial antiretroviral treatment administered as single vs. multiple tablet regimens with the same or different components. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2018, 36, 16-20.	0.3	0
40	Pharmacokinetics of darunavir/cobicistat and etravirine alone and co-administered in HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 732-737.	3.0	13
41	Costa "effectiveness of initial antiretroviral treatment administered as single vs. multiple tablet regimens with the same or different components. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2018, 36, 16-20.	0.5	6
42	Antibodies and Antibody Derivatives: New Partners in HIV Eradication Strategies. <i>Frontiers in Immunology</i> , 2018, 9, 2429.	4.8	15
43	Impact of intensification with raltegravir on HIV-1-infected individuals receiving monotherapy with boosted PIs. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1940-1948.	3.0	19
44	Effectiveness of physically ablative and pharmacological treatments for anal condyloma in HIV-infected men. <i>PLoS ONE</i> , 2018, 13, e0199033.	2.5	12
45	CD32 expression is associated to T-cell activation and is not a marker of the HIV-1 reservoir. <i>Nature Communications</i> , 2018, 9, 2739.	12.8	61
46	High risk and probability of progression to osteoporosis at 10 years in HIV-infected individuals: the role of PIs. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2452-2459.	3.0	6
47	ADAR1 affects HCV infection by modulating innate immune response. <i>Antiviral Research</i> , 2018, 156, 116-127.	4.1	27
48	Proteoliposomal formulations of an HIV-1 gp41-based miniprotein elicit a lipid-dependent immunodominant response overlapping the 2F5 binding motif. <i>Scientific Reports</i> , 2017, 7, 40800.	3.3	12
49	Brief Report. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 74, 201-205.	2.1	7
50	Gag-protease coevolution analyses define novel structural surfaces in the HIV-1 matrix and capsid involved in resistance to Protease Inhibitors. <i>Scientific Reports</i> , 2017, 7, 3717.	3.3	13
51	SAMHD1 is active in cycling cells permissive to HIV-1 infection. <i>Antiviral Research</i> , 2017, 142, 123-135.	4.1	18
52	RNA editing by ADAR1 regulates innate and antiviral immune functions in primary macrophages. <i>Scientific Reports</i> , 2017, 7, 13339.	3.3	43
53	Preserved immune functionality and high CMV-specific T-cell responses in HIV-infected individuals with poor CD4+ T-cell immune recovery. <i>Scientific Reports</i> , 2017, 7, 11711.	3.3	12
54	Evaluation of the Innate Immune Modulator Acitretin as a Strategy To Clear the HIV Reservoir. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	22

#	ARTICLE	IF	CITATIONS
55	Clinical and Emotional Factors Related to Erectile Dysfunction in HIV-Infected Men. American Journal of Men's Health, 2017, 11, 647-653.	1.6	19
56	Transdermal rivastigmine for HIV-associated cognitive impairment: A randomized pilot study. PLoS ONE, 2017, 12, e0182547.	2.5	8
57	Elevated humoral response to cytomegalovirus in HIV-infected individuals with poor CD4+ T-cell immune recovery. PLoS ONE, 2017, 12, e0184433.	2.5	17
58	P-glycoprotein (<i>ABC1</i>) activity decreases raltegravir disposition in primary CD4+P-gp ^{high} cells and correlates with HIV-1 viral load. Journal of Antimicrobial Chemotherapy, 2016, 71, 2782-2792.	3.0	16
59	The G1/S Specific Cyclin D2 Is a Regulator of HIV-1 Restriction in Non-proliferating Cells. PLoS Pathogens, 2016, 12, e1005829.	4.7	32
60	Switching from a ritonavir-boosted PI to dolutegravir as an alternative strategy in virologically suppressed HIV-infected individuals. Journal of Antimicrobial Chemotherapy, 2016, 72, dkw504.	3.0	9
61	Long-term HIV-1 infection induces an antiviral state in primary macrophages. Antiviral Research, 2016, 133, 145-155.	4.1	14
62	Nonhuman TRIM5 Variants Enhance Recognition of HIV-1-Infected Cells by CD8 + T Cells. Journal of Virology, 2016, 90, 8552-8562.	3.4	11
63	Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy. JAMA - Journal of the American Medical Association, 2016, 316, 171.	7.4	1,076
64	Lack of concordance between residual viremia and viral variants driving de novo infection of CD4+ T cells on ART. Retrovirology, 2016, 13, 51.	2.0	14
65	Antiretroviral therapy suppressed participants with low CD4+ T-cell counts segregate according to opposite immunological phenotypes. Aids, 2016, 30, 2275-2287.	2.2	10
66	Treatment intensification followed by interleukin-7 reactivates HIV without reducing total HIV DNA. Aids, 2016, 30, 221-230.	2.2	59
67	Withdrawing inactive NRTIs in HIV-1 subjects with suppressed viraemia: a randomized trial. Journal of Antimicrobial Chemotherapy, 2016, 71, 1346-1351.	3.0	3
68	Nitrogen positional scanning in tetramines active against HIV-1 as potential CXCR4 inhibitors. Organic and Biomolecular Chemistry, 2016, 14, 1455-1472.	2.8	2
69	Removal of Dolutegravir by Hemodialysis in HIV-Infected Patients with End-Stage Renal Disease. Antimicrobial Agents and Chemotherapy, 2016, 60, 2564-2566.	3.2	15
70	Gut Microbiota Linked to Sexual Preference and HIV Infection. EBioMedicine, 2016, 5, 135-146.	6.1	328
71	Management of bone mineral density in HIV-infected patients. Expert Opinion on Pharmacotherapy, 2016, 17, 845-852.	1.8	4
72	Short Communication: Efficacy and Safety of Treatment Simplification to Lopinavir/Ritonavir or Darunavir/Ritonavir Monotherapy: A Randomized Clinical Trial. AIDS Research and Human Retroviruses, 2016, 32, 452-455.	1.1	9

#	ARTICLE	IF	CITATIONS
73	Inhibition of herpes simplex virus type 1 by the CDK6 inhibitor PD-0332991 (palbociclib) through the control of SAMHD1. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 387-394.	3.0	39
74	Short-term Treatment With Interferon Alfa Diminishes Expression of HIV-1 and Reduces CD4 ⁺ T-Cell Activation in Patients Coinfected With HIV and Hepatitis C Virus and Receiving Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2016, 213, 1008-1012.	4.0	36
75	Monotherapy with boosted PIs as an ART simplification strategy in clinical practice. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1124-1129.	3.0	13
76	Reduced darunavir dose is as effective in maintaining HIV suppression as the standard dose in virologically suppressed HIV-infected patients: a randomized clinical trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1139-1145.	3.0	21
77	Increased ex vivo cell death of central memory CD4 T cells in treated HIV infected individuals with unsatisfactory immune recovery. <i>Journal of Translational Medicine</i> , 2015, 13, 230.	4.4	33
78	Week 48 efficacy and central nervous system analysis of darunavir/ritonavir monotherapy versus darunavir/ritonavir with two nucleoside analogues. <i>Aids</i> , 2015, 29, 1811-1820.	2.2	29
79	Gp120/CD4 Blocking Antibodies Are Frequently Elicited in ART-Naïve Chronically HIV-1 Infected Individuals. <i>PLoS ONE</i> , 2015, 10, e0120648.	2.5	5
80	A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques. <i>Journal of Translational Medicine</i> , 2015, 13, 60.	4.4	84
81	CCR5 Δ 32 homozygous cord blood allogeneic transplantation in a patient with HIV: a case report. <i>Lancet HIV</i> , 2015, 2, e236-e242.	4.7	52
82	HIV-1 Reservoir Dynamics after Vaccination and Antiretroviral Therapy Interruption Are Associated with Dendritic Cell Vaccine-Induced T Cell Responses. <i>Journal of Virology</i> , 2015, 89, 9189-9199.	3.4	33
83	Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naïve adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. <i>Lancet HIV</i> , 2015, 2, e127-e136.	4.7	180
84	The Lipid-Lowering Effect of Tenofovir/Emtricitabine: A Randomized, Crossover, Double-Blind, Placebo-Controlled Trial. <i>Clinical Infectious Diseases</i> , 2015, 61, 403-408.	5.8	100
85	Cyclin D3-dependent control of the dNTP pool and HIV-1 replication in human macrophages. <i>Cell Cycle</i> , 2015, 14, 1657-1665.	2.6	40
86	Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1833-1842.	3.0	56
87	Virological failure to raltegravir in Spain: incidence, prevalence and clinical consequences. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 3087-3095.	3.0	13
88	Alternative Effector-Function Profiling Identifies Broad HIV-Specific T-Cell Responses in Highly HIV-Exposed Individuals Who Remain Uninfected. <i>Journal of Infectious Diseases</i> , 2015, 211, 936-946.	4.0	18
89	Effectiveness of a Treatment Switch to Nevirapine plus Tenofovir and Emtricitabine (or Lamivudine) in Adults with HIV-1 Suppressed Viremia. <i>PLoS ONE</i> , 2015, 10, e0128131.	2.5	4
90	Classification Models for Neurocognitive Impairment in HIV Infection Based on Demographic and Clinical Variables. <i>PLoS ONE</i> , 2014, 9, e107625.	2.5	19

#	ARTICLE	IF	CITATIONS
91	Different Plasma Markers of Inflammation Are Influenced by Immune Recovery and cART Composition or Intensification in Treated HIV Infected Individuals. <i>PLoS ONE</i> , 2014, 9, e114142.	2.5	27
92	Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGO. <i>Journal of the International AIDS Society</i> , 2014, 17, 19490.	3.0	41
93	Randomized, crossover, double-blind, placebo-controlled trial to assess the lipid lowering effect of co-formulated TDF/FTC. <i>Journal of the International AIDS Society</i> , 2014, 17, 19550.	3.0	6
94	Improvement in bone mineral density after switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: two-centre randomized pilot study (OsteoTDF study). <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3368-3371.	3.0	43
95	Peak Bone Mass in Young HIV-Infected Patients Compared With Healthy Controls. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 65, 207-212.	2.1	30
96	IFNL4 rs469415590 variant is a better predictor than rs12979860 of pegylated interferon-alpha/ribavirin therapy failure in hepatitis C virus/HIV-1 coinfecting patients. <i>Aids</i> , 2014, 28, 133-136.	2.2	34
97	Incidence and clinical management of oral human papillomavirus infection in men: a series of key short messages. <i>Expert Review of Anti-Infective Therapy</i> , 2014, 12, 947-957.	4.4	5
98	Palbociclib, a selective inhibitor of cyclin-dependent kinase4/6, blocks HIV-1 reverse transcription through the control of sterile Î± motif and HD domain-containing protein-1 (SAMHD1) activity. <i>Aids</i> , 2014, 28, 2213-2222.	2.2	45
99	Effect of lithium on HIV-1 expression and proviral reservoir size in the CD4+ T cells of antiretroviral therapy suppressed patients. <i>Aids</i> , 2014, 28, 2157-2159.	2.2	17
100	Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naïve adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. <i>Lancet</i> , The, 2014, 383, 2222-2231.	13.7	430
101	p21 regulates the HIV-1 restriction factor SAMHD1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E1322-4.	7.1	51
102	Zinc Finger Endonuclease Targeting <i>PSIP1</i> Inhibits HIV-1 Integration. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 4318-4327.	3.2	15
103	Cell Cycle Control and HIV-1 Susceptibility Are Linked by CDK6-Dependent CDK2 Phosphorylation of SAMHD1 in Myeloid and Lymphoid Cells. <i>Journal of Immunology</i> , 2014, 193, 1988-1997.	0.8	118
104	Gene editing using a zinc-finger nuclease mimicking the CCR5Î”32 mutation induces resistance to CCR5-using HIV-1. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1755-1759.	3.0	26
105	SAMHD1 Specifically Affects the Antiviral Potency of Thymidine Analog HIV Reverse Transcriptase Inhibitors. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 4804-4813.	3.2	30
106	Characterization of the Influence of Mediator Complex in HIV-1 Transcription. <i>Journal of Biological Chemistry</i> , 2014, 289, 27665-27676.	3.4	26
107	Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe. <i>BMC Infectious Diseases</i> , 2014, 14, 407.	2.9	43
108	Increased expression of SAMHD1 in a subset of HIV-1 elite controllers. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3057-3060.	3.0	26

#	ARTICLE	IF	CITATIONS
109	Effectiveness of Mindfulness-Based Cognitive Therapy on the Quality of Life, Emotional Status, and CD4 Cell Count of Patients Aging with HIV Infection. <i>AIDS and Behavior</i> , 2014, 18, 676-685.	2.7	61
110	Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4A: a phase 2 randomised, double-blind, placebo-controlled trial. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 291-300.	9.1	100
111	Effectiveness of Efavirenz Compared with Ritonavir-Boosted Protease-Inhibitor-Based Regimens as Initial Therapy for Patients with Plasma HIV-1 RNA above 100,000 Copies/ML. <i>Antiviral Therapy</i> , 2014, 19, 569-577.	1.0	8
112	Association between first-year virological response to raltegravir and long-term outcomes in treatment-experienced patients with HIV-1 infection. <i>Antiviral Therapy</i> , 2014, 20, 307-315.	1.0	7
113	Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection. <i>Aids</i> , 2014, 28, 325-334.	2.2	62
114	Randomised Study to Assess the Efficacy and Safety of Once-Daily Etravirine-Based Regimen as a Switching Strategy in HIV-Infected Patients Receiving a Protease Inhibitor-Containing Regimen. Etraswitch Study. <i>PLoS ONE</i> , 2014, 9, e84676.	2.5	11
115	Effect of Maraviroc Intensification on HIV-1-Specific T Cell Immunity in Recently HIV-1-Infected Individuals. <i>PLoS ONE</i> , 2014, 9, e87334.	2.5	15
116	Patterns of Transmitted HIV Drug Resistance in Europe Vary by Risk Group. <i>PLoS ONE</i> , 2014, 9, e94495.	2.5	32
117	Screening NK-, B- and T-cell phenotype and function in patients suffering from Chronic Fatigue Syndrome. <i>Journal of Translational Medicine</i> , 2013, 11, 68.	4.4	92
118	Expansion of antibody secreting cells and modulation of neutralizing antibody activity in HIV infected individuals undergoing structured treatment interruptions. <i>Journal of Translational Medicine</i> , 2013, 11, 48.	4.4	3
119	The infectious synapse formed between mature dendritic cells and CD4+T cells is independent of the presence of the HIV-1 envelope glycoprotein. <i>Retrovirology</i> , 2013, 10, 42.	2.0	38
120	Assessing main death pathways in T lymphocytes from HIV infected individuals. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2013, 83A, 648-658.	1.5	13
121	Stable HIV-1 integrase diversity during initial HIV-1 RNA Decay suggests complete blockade of plasma HIV-1 replication by effective raltegravir-containing salvage therapy. <i>Virology Journal</i> , 2013, 10, 350.	3.4	3
122	Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study. <i>Journal of Infectious Diseases</i> , 2013, 207, 740-748.	4.0	271
123	HLA class I protective alleles in an HIV-1-infected subject homozygous for CCR5-Δ32. <i>Immunobiology</i> , 2013, 218, 543-547.	1.9	5
124	A Dendritic Cell-Based Vaccine Elicits T Cell Responses Associated with Control of HIV-1 Replication. <i>Science Translational Medicine</i> , 2013, 5, 166ra2.	12.4	193
125	Simultaneous Pharmacogenetics-Based Population Pharmacokinetic Analysis of Darunavir and Ritonavir in HIV-Infected Patients. <i>Clinical Pharmacokinetics</i> , 2013, 52, 543-553.	3.5	32
126	Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 587-596.	9.1	119

#	ARTICLE	IF	CITATIONS
127	Learning from drug changes in antiretroviral therapy. <i>Aids</i> , 2013, 27, 833-834.	2.2	7
128	Natural History of Human Papillomavirus Infections Involving Anal, Penile, and Oral Sites Among HIV-Positive Men. <i>Sexually Transmitted Diseases</i> , 2013, 40, 3-10.	1.7	98
129	Dynamics of CD8 T-Cell Activation After Discontinuation of HIV Treatment Intensification. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, 152-160.	2.1	21
130	Early but limited effects of raltegravir intensification on CD4 T cell reconstitution in HIV-infected patients with an immunodiscordant response to antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2358-2362.	3.0	28
131	Distribution of Human Papillomavirus Genotypes in Anal Cytological and Histological Specimens from HIV-Infected Men Who Have Sex with Men and Men Who Have Sex with Women. <i>Diseases of the Colon and Rectum</i> , 2013, 56, 1043-1052.	1.3	44
132	HIV exposed seronegative individuals show antibodies specifically recognizing native HIV envelope glycoprotein. <i>Aids</i> , 2013, 27, 1375-1385.	2.2	15
133	Immunodiscordant responses to HAART – mechanisms and consequences. <i>Expert Review of Clinical Immunology</i> , 2013, 9, 1135-1149.	3.0	79
134	Restriction of HIV-1 Replication in Primary Macrophages by IL-12 and IL-18 through the Upregulation of SAMHD1. <i>Journal of Immunology</i> , 2013, 190, 4736-4741.	0.8	52
135	Prevalence, Clearance, and Incidence of Human Papillomavirus Type-Specific Infection at the Anal and Penile Site of HIV-Infected Men. <i>Sexually Transmitted Diseases</i> , 2013, 40, 611-618.	1.7	46
136	HIV-1 Tropism Testing in Subjects Achieving Undetectable HIV-1 RNA: Diagnostic Accuracy, Viral Evolution and Compartmentalization. <i>PLoS ONE</i> , 2013, 8, e67085.	2.5	12
137	Treatment Intensification with Raltegravir in Subjects with Sustained HIV-1 Viraemia Suppression: A Randomized 48-Week Study. <i>Antiviral Therapy</i> , 2012, 17, 355-364.	1.0	108
138	Siglec-1 Is a Novel Dendritic Cell Receptor That Mediates HIV-1 Trans-Infection Through Recognition of Viral Membrane Gangliosides. <i>PLoS Biology</i> , 2012, 10, e1001448.	5.6	208
139	Evaluation of the Cytopathicity (Fusion/Hemifusion) of Patient-Derived HIV-1 Envelope Glycoproteins Comparing Two Effector Cell Lines. <i>Journal of Biomolecular Screening</i> , 2012, 17, 727-737.	2.6	9
140	Antiretroviral Agents Effectively Block HIV Replication after Cell-to-Cell Transfer. <i>Journal of Virology</i> , 2012, 86, 8773-8780.	3.4	37
141	Trans-infection but Not Infection from within Endosomal Compartments after Cell-to-cell HIV-1 Transfer to CD4+ T Cells. <i>Journal of Biological Chemistry</i> , 2012, 287, 32017-32026.	3.4	12
142	Mutations in the protease gene associated with virological failure to lopinavir/ritonavir-containing regimens. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 1462-1469.	3.0	4
143	Novel Two-Round Phenotypic Assay for Protease Inhibitor Susceptibility Testing of Recombinant and Primary HIV-1 Isolates. <i>Journal of Clinical Microbiology</i> , 2012, 50, 3909-3916.	3.9	6
144	HIV-1 Capture and Antigen Presentation by Dendritic Cells: Enhanced Viral Capture Does Not Correlate with Better T Cell Activation. <i>Journal of Immunology</i> , 2012, 188, 6036-6045.	0.8	21

#	ARTICLE	IF	CITATIONS
145	Efficacy and Safety of Rilpivirine (TMC278) Versus Efavirenz at 48 Weeks in Treatment-Naive HIV-1-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2012, 60, 33-42.	2.1	151
146	Raltegravir intensification shows differing effects on CD8 and CD4 T cells in HIV-infected HAART-suppressed individuals with poor CD4 T-cell recovery. <i>Aids</i> , 2012, 26, 2285-2293.	2.2	44
147	Emotional Impact of Premature Aging Symptoms in Long-Term Treated HIV-Infected Subjects. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2012, 59, e5-e8.	2.1	10
148	Genotypic and Phenotypic Characterization of HIV-1 Isolates Obtained From Patients on Rilpivirine Therapy Experiencing Virologic Failure in the Phase 3 ECHO and THRIVE Studies. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2012, 59, 39-46.	2.1	155
149	Alleles at rs4273729 in the chromosome 6 do not predict response to peg-interferon- α and ribavirin therapy in hepatitis C virus/HIV-1-coinfected patients. <i>Aids</i> , 2012, 26, 1973-1974.	2.2	3
150	Similarly high prevalence of hypovitaminosis D in HIV-infected subjects with and without low bone mineral density. <i>Future Virology</i> , 2012, 7, 1127-1134.	1.8	3
151	Diverse combinatorial design, synthesis and <i>in vitro</i> evaluation of new HEPT analogues as potential non-nucleoside HIV-1 reverse transcription inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2012, 54, 159-174.	5.5	18
152	Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 27-35.	9.1	160
153	LDL subclasses and lipoprotein-phospholipase A2 activity in suppressed HIV-infected patients switching to raltegravir: Spiral substudy. <i>Atherosclerosis</i> , 2012, 225, 200-207.	0.8	30
154	Psychological stress is associated with high levels of IL-6 in HIV-1 infected individuals on effective combined antiretroviral treatment. <i>Brain, Behavior, and Immunity</i> , 2012, 26, 568-572.	4.1	35
155	Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients. <i>Retrovirology</i> , 2012, 9, 81.	2.0	23
156	High rate of reversibility of renal damage in a cohort of HIV-infected patients receiving tenofovir-containing antiretroviral therapy. <i>Antiviral Research</i> , 2012, 96, 65-69.	4.1	39
157	CTL Responses of High Functional Avidity and Broad Variant Cross-Reactivity Are Associated with HIV Control. <i>PLoS ONE</i> , 2012, 7, e29717.	2.5	117
158	Viremic HIV Infected Individuals with High CD4 T Cells and Functional Envelope Proteins Show Anti-gp41 Antibodies with Unique Specificity and Function. <i>PLoS ONE</i> , 2012, 7, e30330.	2.5	13
159	Deciphering the Interleukin 28B Variants That Better Predict Response to Pegylated Interferon- α and Ribavirin Therapy in HCV/HIV-1 Coinfected Patients. <i>PLoS ONE</i> , 2012, 7, e31016.	2.5	35
160	The HR2 polymorphism N140I in the HIV-1 gp41 combined with the HR1 V38A mutation is associated with a less cytopathic phenotype. <i>Retrovirology</i> , 2012, 9, 15.	2.0	8
161	Antiretroviral Simplification with Darunavir/Ritonavir Monotherapy in Routine Clinical Practice: Safety, Effectiveness, and Impact on Lipid Profile. <i>PLoS ONE</i> , 2012, 7, e37442.	2.5	21
162	Time of Progression to Osteopenia/Osteoporosis in Chronically HIV-Infected Patients: Screening DXA Scan. <i>PLoS ONE</i> , 2012, 7, e46031.	2.5	16

#	ARTICLE	IF	CITATIONS
163	RNA Interference as a Tool for Exploring HIV-1 Robustness. <i>Journal of Molecular Biology</i> , 2011, 413, 84-96.	4.2	17
164	A cell-to-cell HIV transfer assay identifies humoral responses with broad neutralization activity. <i>Vaccine</i> , 2011, 29, 5250-5259.	3.8	38
165	Ex vivo production of autologous whole inactivated HIV-1 for clinical use in therapeutic vaccines. <i>Vaccine</i> , 2011, 29, 5711-5724.	3.8	9
166	Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. <i>Lancet Infectious Diseases</i> , The, 2011, 11, 363-371.	9.1	345
167	Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naïve adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. <i>Lancet</i> , The, 2011, 378, 229-237.	13.7	352
168	Effect of an induction period of pegylated interferon- α 2a and ribavirin on early virological response in HIV-HCV-coinfected patients: results from the CORAL-2 study. <i>Antiviral Therapy</i> , 2011, 16, 833-841.	1.0	3
169	Human Papillomavirus Genotype Distribution and Human Papillomavirus 16 and Human Papillomavirus 18 Genomic Integration in Invasive and In Situ Cervical Carcinoma in Human Immunodeficiency Virus-Infected Women. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 1486-1490.	2.5	13
170	Development of resistance to VIR-353 with cross-resistance to the natural HIV-1 entry virus inhibitory peptide (VIRIP). <i>Aids</i> , 2011, 25, 1557-1583.	2.2	17
171	Clinical implications of fixed-dose coformulations of antiretrovirals on the outcome of HIV-1 therapy. <i>Aids</i> , 2011, 25, 1683-1690.	2.2	43
172	Combined Antiretroviral Therapy and Immune Pressure Lead to In Vivo HIV-1 Recombination With Ancestral Viral Genomes. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 57, 109-117.	2.1	12
173	Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccine. <i>Aids</i> , 2011, 25, 27-36.	2.2	40
174	Hyaluronic Acid Levels Predict Increased Risk of Non-Aids Death in Hepatitis-Coinfected Persons Interrupting Antiretroviral Therapy in the Smart Study. <i>Antiviral Therapy</i> , 2011, 16, 667-675.	1.0	16
175	The reconstitution of the thymus in immunosuppressed individuals restores CD4-specific cellular and humoral immune responses. <i>Immunology</i> , 2011, 133, 318-328.	4.4	12
176	Drug uptake transporters in antiretroviral therapy. , 2011, 132, 268-279.		62
177	Compensatory mutations rescue the virus replicative capacity of VIRIP-resistant HIV-1. <i>Antiviral Research</i> , 2011, 92, 479-483.	4.1	27
178	Diarylpyrimidine~Dihydrobenzoxypyrimidine Hybrids: New, Wide-Spectrum Anti-HIV-1 Agents Active at (Sub)-Nanomolar Level. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 3091-3096.	6.4	47
179	Short Communication: High Effectiveness of Etravirine in Routine Clinical Practice in Treatment-Experienced HIV Type 1-Infected Patients. <i>AIDS Research and Human Retroviruses</i> , 2011, 27, 713-717.	1.1	7
180	Plasma and Intracellular (Peripheral Blood Mononuclear Cells) Pharmacokinetics of Once-Daily Raltegravir (800 Milligrams) in HIV-Infected Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 72-75.	3.2	24

#	ARTICLE	IF	CITATIONS
181	Herb-Drug Interaction between Echinacea purpurea and Darunavir-Ritonavir in HIV-Infected Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 326-330.	3.2	35
182	Efficacy and safety of nucleoside reverse transcriptase inhibitor-sparing salvage therapy for multidrug-resistant HIV-1 infection based on new-class and new-generation antiretrovirals. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 358-362.	3.0	20
183	Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1886-1896.	3.0	56
184	Î²5 Integrin Is the Major Contributor to the Î±v Integrin-Mediated Blockade of HIV-1 Replication. <i>Journal of Immunology</i> , 2011, 186, 464-470.	0.8	21
185	The Role of Inactive Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Salvage Therapy for Drug-Resistant HIV-1 Infection in the Era of New Classes and New Generation Antiretrovirals. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 58, e46-e48.	2.1	1
186	Complexity and Catalytic Efficiency of Hepatitis C Virus (HCV) NS3 and NS4A Protease Quasispecies Influence Responsiveness to Treatment with Pegylated Interferon plus Ribavirin in HCV/HIV-Coinfected Patients. <i>Journal of Virology</i> , 2011, 85, 5961-5969.	3.4	17
187	Connection Domain Mutations in HIV-1 Reverse Transcriptase Do Not Impact Etravirine Susceptibility and Virologic Responses to Etravirine-Containing Regimens. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 2872-2879.	3.2	31
188	Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 901-911.	3.0	13
189	Deep Molecular Characterization of HIV-1 Dynamics under Suppressive HAART. <i>PLoS Pathogens</i> , 2011, 7, e1002314.	4.7	55
190	A376S in the Connection Subdomain of HIV-1 Reverse Transcriptase Confers Increased Risk of Virological Failure to Nevirapine Therapy. <i>Journal of Infectious Diseases</i> , 2011, 204, 741-752.	4.0	19
191	A Therapeutic Dendritic Cell-Based Vaccine for HIV-1 Infection. <i>Journal of Infectious Diseases</i> , 2011, 203, 473-478.	4.0	105
192	Effect of Nevirapine on the Steady-State Trough Concentrations of Atazanavir in HIV-Infected Patients Receiving Atazanavir/Ritonavir. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 93-96.	2.0	6
193	Frequent hepatitis B virus rebound among HIV-1 hepatitis B virus-coinfected patients following antiretroviral therapy interruption. <i>Aids</i> , 2010, 24, 857-865.	2.2	59
194	Treatment simplification to once daily darunavir/ritonavir guided by the darunavir inhibitory quotient in heavily pretreated HIV-infected patients. <i>Antiviral Therapy</i> , 2010, 15, 219-225.	1.0	10
195	Genotypic and phenotypic evolution of HIV type-1 protease during <i>in vitro</i> sequential or concomitant combination of atazanavir and amprenavir. <i>Antiviral Therapy</i> , 2010, 15, 431-436.	1.0	2
196	Interruptions of antiretroviral therapy in human immunodeficiency virus infection: are they detrimental to neurocognitive functioning?. <i>Journal of NeuroVirology</i> , 2010, 16, 208-218.	2.1	13
197	Clinical management of HIV-1 resistance. <i>Antiviral Research</i> , 2010, 85, 245-265.	4.1	77
198	Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure. <i>Antiviral Research</i> , 2010, 88, 281-286.	4.1	28

#	ARTICLE	IF	CITATIONS
199	Novel Monocyclam Derivatives as HIV Entry Inhibitors: Design, Synthesis, Anti-HIV Evaluation, and Their Interaction with the CXCR4 Co-receptor. <i>ChemMedChem</i> , 2010, 5, 1272-1281.	3.2	17
200	HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. <i>Nature Medicine</i> , 2010, 16, 460-465.	30.7	500
201	IL28B SNP rs8099917 Is Strongly Associated with Pegylated Interferon- α and Ribavirin Therapy Treatment Failure in HCV/HIV-1 Coinfected Patients. <i>PLoS ONE</i> , 2010, 5, e13771.	2.5	71
202	Nadir CD4 T Cell Count as Predictor and High CD4 T Cell Intrinsic Apoptosis as Final Mechanism of Poor CD4 T Cell Recovery in Virologically Suppressed HIV-1 Infected Patients: Clinical Implications. <i>Clinical Infectious Diseases</i> , 2010, 50, 1300-1308.	5.8	133
203	Clinical Implications of Genotypic Resistance to the Newer Antiretroviral Drugs in HIV-1 Infected Patients with Virological Failure. <i>Clinical Infectious Diseases</i> , 2010, 50, 872-881.	5.8	51
204	Different selection patterns of resistance and cross-resistance to HIV-1 agents targeting CCR5. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 417-424.	3.0	18
205	ZNRD1 (Zinc Ribbon Domain-Containing 1) Is a Host Cellular Factor That Influences HIV-1 Replication and Disease Progression. <i>Clinical Infectious Diseases</i> , 2010, 50, 1022-1032.	5.8	42
206	Minimal Removal of Raltegravir by Hemodialysis in HIV-Infected Patients with End-Stage Renal Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 3047-3048.	3.2	23
207	Long-Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment-Experienced Patients with Drug-Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials. <i>Clinical Infectious Diseases</i> , 2010, 50, 605-612.	5.8	196
208	Efficacy and Safety of Ritonavir Dose Reduction Based on the Tipranavir Inhibitory Quotient in HIV-Infected Patients on Salvage Antiretroviral Therapy with Tipranavir/Ritonavir. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 1191-1196.	1.1	2
209	ADSI-1 Inhibits HIV-1 Entry by Interacting with gp120 and Does Not Block Fusion-Active gp41 Core Formation. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 4487-4492.	3.2	25
210	Could CD4 Capture by CD^8^+ T Cells Play a Role in HIV Spreading?. <i>Journal of Biomedicine and Biotechnology</i> , 2010, 2010, 1-10.	3.0	10
211	CD4 T-cell hyperactivation and susceptibility to cell death determine poor CD4 T-cell recovery during suppressive HAART. <i>Aids</i> , 2010, 24, 959-968.	2.2	114
212	The HIV-1 integrase genotype strongly predicts raltegravir susceptibility but not viral fitness of primary virus isolates. <i>Aids</i> , 2010, 24, 17-25.	2.2	33
213	High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study. <i>Aids</i> , 2010, 24, 2827-2833.	2.2	140
214	Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials. <i>Antiviral Therapy</i> , 2010, 15, 1045-1052.	1.0	96
215	Costs to Achieve Undetectable HIV RNA with Darunavir-Containing Highly Active Antiretroviral Therapy in Highly Pretreated Patients. <i>Pharmacoeconomics</i> , 2010, 28, 69-81.	3.3	3
216	Human Papillomavirus 16 Integration and Risk Factors Associated in Anal Samples of HIV-1 Infected Men. <i>Sexually Transmitted Diseases</i> , 2010, 37, 311-315.	1.7	16

#	ARTICLE	IF	CITATIONS
217	A Double-blind, Placebo-Controlled Trial of Maraviroc in Treatment-Experienced Patients Infected with Non-R5 HIV-1. <i>Journal of Infectious Diseases</i> , 2009, 199, 1638-1647.	4.0	127
218	Efficacy and Safety of Switching from Enfuvirtide to Raltegravir in Patients with Virological Suppression. <i>HIV Clinical Trials</i> , 2009, 10, 432-438.	2.0	14
219	A Step Ahead on the HIV Collaboratory. <i>Science</i> , 2009, 324, 1264-1265.	12.6	4
220	The Changing Face of HIV/AIDS in Treated Patients. <i>Current HIV Research</i> , 2009, 7, 365-377.	0.5	28
221	Transmission of Drug-Resistant HIV-1 Is Stabilizing in Europe. <i>Journal of Infectious Diseases</i> , 2009, 200, 1503-1508.	4.0	213
222	HIV endocytosis after dendritic cell to T cell viral transfer leads to productive virus infection. <i>Antiviral Research</i> , 2009, 83, 94-98.	4.1	26
223	Prescribing and using self-injectable antiretrovirals: How concordant are physician and patient perspectives?. <i>AIDS Research and Therapy</i> , 2009, 6, 2.	1.7	6
224	Secretion of interferon- β by human macrophages demonstrated at the single-cell level after costimulation with interleukin (IL)-2 plus IL-18. <i>Immunology</i> , 2009, 126, 386-393.	4.4	173
225	On the steps of cell-to-cell HIV transmission between CD4 T cells. <i>Retrovirology</i> , 2009, 6, 89.	2.0	38
226	Pilot Pharmacokinetic Study of Human Immunodeficiency Virus-Infected Patients Receiving Tenofovir Disoproxil Fumarate (TDF): Investigation of Systemic and Intracellular Interactions between TDF and Abacavir, Lamivudine, or Lopinavir-Ritonavir. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 1937-1943.	3.2	68
227	Transport of Lamivudine [(-)-2,3-Dideoxy-3-thiacytidine] and High-Affinity Interaction of Nucleoside Reverse Transcriptase Inhibitors with Human Organic Cation Transporters 1, 2, and 3. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009, 329, 252-261.	2.5	125
228	Capture and transfer of HIV-1 particles by mature dendritic cells converges with the exosome-dissemination pathway. <i>Blood</i> , 2009, 113, 2732-2741.	1.4	208
229	A Randomized, Open-Label Study of a Nucleoside Analogue Reverse Transcriptase Inhibitor-Sparing Regimen in Antiretroviral-Naive HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 50, 335-337.	2.1	8
230	Evaluation of the anti-HIV activity of natalizumab, an antibody against integrin alpha4. <i>Aids</i> , 2009, 23, 266-268.	2.2	16
231	Epidemiological Data of Different Human Papillomavirus Genotypes in Cervical Specimens of HIV-1-Infected Women Without History of Cervical Pathology. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 50, 168-175.	2.1	24
232	Antigp41 antibodies fail to block early events of virological synapses but inhibit HIV spread between T cells. <i>Aids</i> , 2009, 23, 183-188.	2.2	70
233	A Simplification Trial Switching From Nucleoside Reverse Transcriptase Inhibitors to Once-Daily Fixed-Dose Abacavir/Lamivudine or Tenofovir/Emtricitabine in HIV-1-Infected Patients With Virological Suppression. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 51, 290-297.	2.1	73
234	Cell adhesion through α V-containing integrins is required for efficient HIV-1 infection in macrophages. <i>Blood</i> , 2009, 113, 1278-1286.	1.4	33

#	ARTICLE	IF	CITATIONS
235	Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression. <i>Antiviral Therapy</i> , 2009, 14, 195-201.	1.0	51
236	Discovery of Novel Non-Cyclam Polynitrogenated CXCR4 Coreceptor Inhibitors. <i>ChemMedChem</i> , 2008, 3, 1549-1557.	3.2	17
237	HIV-1 resistance to the anti-HIV activity of a shRNA targeting a dual-coding region. <i>Virology</i> , 2008, 372, 421-429.	2.4	17
238	A clathrin-dynamin-dependent endocytic pathway for the uptake of HIV-1 by direct T cell-T cell transmission. <i>Antiviral Research</i> , 2008, 80, 185-193.	4.1	62
239	HIV transfer between CD4 T cells does not require LFA-1 binding to ICAM-1 and is governed by the interaction of HIV envelope glycoprotein with CD4. <i>Retrovirology</i> , 2008, 5, 32.	2.0	46
240	Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection. <i>New England Journal of Medicine</i> , 2008, 359, 339-354.	27.0	699
241	A wide range of NS3/4A protease catalytic efficiencies in HCV-infected individuals. <i>Virus Research</i> , 2008, 131, 260-270.	2.2	17
242	Maraviroc for Previously Treated Patients with R5 HIV-1 Infection. <i>New England Journal of Medicine</i> , 2008, 359, 1429-1441.	27.0	708
243	Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection. <i>New England Journal of Medicine</i> , 2008, 359, 355-365.	27.0	498
244	Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection: 2008 Recommendations of an International AIDS Society-USA Panel. <i>Clinical Infectious Diseases</i> , 2008, 47, 266-285.	5.8	428
245	Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study. <i>Aids</i> , 2008, 22, 2187-2198.	2.2	37
246	Transmitted Drug Resistant HIV-1 and Association With Virologic and CD4 Cell Count Response to Combination Antiretroviral Therapy in the EuroSIDA Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 48, 324-333.	2.1	46
247	Nadir CD4 Cell Count Predicts Neurocognitive Impairment in HIV-Infected Patients. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 1301-1307.	1.1	87
248	A randomized, controlled study evaluating an induction treatment strategy in which enfuvirtide was added to an oral, highly active antiretroviral therapy regimen in treatment-experienced patients: the INTENSE study. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 1374-1378.	3.0	6
249	Expression and Functionality of Anti-Human Immunodeficiency Virus and Anticancer Drug Uptake Transporters in Immune Cells. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008, 324, 558-567.	2.5	66
250	Opportunistic Disease and Mortality in Patients Coinfected with Hepatitis B or C Virus in the Strategic Management of Antiretroviral Therapy (SMART) Study. <i>Clinical Infectious Diseases</i> , 2008, 47, 1468-1475.	5.8	53
251	Darunavir Inhibitory Quotient Predicts the 48-Week Virological Response to Darunavir-Based Salvage Therapy in Human Immunodeficiency Virus-Infected Protease Inhibitor-Experienced Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 3928-3932.	3.2	24
252	Anti-HIV Activity and Resistance Profile of the CXC Chemokine Receptor 4 Antagonist POL3026. <i>Molecular Pharmacology</i> , 2008, 73, 1264-1273.	2.3	55

#	ARTICLE	IF	CITATIONS
253	Drug-Resistance Mutations Number and K70R or T215Y/F Substitutions Predict Treatment Resumption during Guided Treatment Interruptions. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 725-732.	1.1	4
254	Rational use of antiretroviral therapy in low-income and middle-income countries: optimizing regimen sequencing and switching. <i>Aids</i> , 2008, 22, 2053-2067.	2.2	26
255	TILT: a randomized controlled trial of interruption of antiretroviral therapy with or without interleukin-2 in HIV-1 infected individuals. <i>Aids</i> , 2008, 22, 737-740.	2.2	6
256	Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452). <i>Aids</i> , 2008, 22, 1313-1322.	2.2	77
257	The Magnitude of Interferon- γ Responses to Human Cytomegalovirus Is Predictive for HIV-1 Disease Progression. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 49, 507-512.	2.1	4
258	HIV-1 escape to CCR5 coreceptor antagonism through selection of CXCR4-using variants in vitro. <i>Aids</i> , 2008, 22, 23-31.	2.2	46
259	Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA. <i>Aids</i> , 2008, 22, 367-376.	2.2	43
260	Partial Immunological and Mitochondrial Recovery after Reducing Didanosine doses in Patients on Didanosine and Tenofovir-Based Regimens. <i>Antiviral Therapy</i> , 2008, 13, 231-240.	1.0	5
261	Variability in the Plasma Concentration of Efavirenz and Nevirapine is Associated with Genotypic Resistance after Treatment Interruption. <i>Antiviral Therapy</i> , 2008, 13, 945-951.	1.0	21
262	Raltegravir Susceptibility and Fitness Progression of HIV Type-1 Integrase in Patients on Long-Term Antiretroviral Therapy. <i>Antiviral Therapy</i> , 2008, 13, 881-893.	1.0	22
263	Differences in Virological Response to Pegylated Interferon and Ribavirin between Hepatitis C Virus (Hcv)-Monoinfected and HCV-Hiv-Coinfected Patients. <i>Antiviral Therapy</i> , 2008, 13, 1047-1055.	1.0	22
264	TORO: Ninety-Six-Week Virologic and Immunologic Response and Safety Evaluation of Enfuvirtide with an Optimized Background of Antiretrovirals. <i>AIDS Patient Care and STDs</i> , 2007, 21, 533-543.	2.5	48
265	Relative Fitness and Replication Capacity of a Multinucleoside Analogue-Resistant Clinical Human Immunodeficiency Virus Type 1 Isolate with a Deletion of Codon 69 in the Reverse Transcriptase Coding Region. <i>Journal of Virology</i> , 2007, 81, 4713-4721.	3.4	23
266	Association between HIV replication and cholesterol in peripheral blood mononuclear cells in HIV-infected patients interrupting HAART. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 61, 400-404.	3.0	11
267	Endoribonuclease-Prepared Short Interfering RNAs Induce Effective and Specific Inhibition of Human Immunodeficiency Virus Type 1 Replication. <i>Journal of Virology</i> , 2007, 81, 10680-10686.	3.4	12
268	Assessing Self-Reported Adherence to HIV Therapy by Questionnaire: The SERAD (Self-Reported) Tj ETQq0 0 0 rgBT /Qverlock 10 Tf 50 1.	1.1	41
269	CCR5 Inhibitors: Promising yet Challenging. <i>Journal of Infectious Diseases</i> , 2007, 196, 178-180.	4.0	14
270	Long-distance interactive expert advice in highly treatment-experienced HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 61, 206-209.	3.0	8

#	ARTICLE	IF	CITATIONS
271	Maturation of Blood-Derived Dendritic Cells Enhances Human Immunodeficiency Virus Type 1 Capture and Transmission. <i>Journal of Virology</i> , 2007, 81, 7559-7570.	3.4	99
272	Fitness Landscape of Human Immunodeficiency Virus Type 1 Protease Quasispecies. <i>Journal of Virology</i> , 2007, 81, 2485-2496.	3.4	56
273	Clinical approach to drug resistance interpretation: expert advice. <i>Current Opinion in HIV and AIDS</i> , 2007, 2, 145-149.	3.8	1
274	Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients. <i>Aids</i> , 2007, 21, 169-178.	2.2	74
275	Compromised Immunologic Recovery in Patients Receiving Tipranavir/Ritonavir Coadministered With Tenofovir and Didanosine in Randomized Evaluation of Strategic Intervention in multidrug-resistant patients with Tipranavir (RESIST) Studies. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 45, 479-481.	2.1	1
276	Safety, Tolerability, and Efficacy of Darunavir (TMC114) with Low-Dose Ritonavir in Treatment-Experienced, Hepatitis B or C Co-infected Patients in POWER 1 and 3. <i>HIV Clinical Trials</i> , 2007, 8, 213-220.	2.0	41
277	Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen. <i>Aids</i> , 2007, 21, 721-732.	2.2	85
278	The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. <i>Aids</i> , 2007, 21, 1273-1281.	2.2	287
279	Complete nucleotide sequence of genotype 4 hepatitis C viruses isolated from patients co-infected with human immunodeficiency virus type 1. <i>Virus Research</i> , 2007, 123, 161-169.	2.2	27
280	Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. <i>Lancet, The</i> , 2007, 369, 1169-1178.	13.7	506
281	Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2007, 370, 39-48.	13.7	437
282	Review: Immunologic Response to Protease Inhibitor-Based Highly Active Antiretroviral Therapy: A Review. <i>AIDS Patient Care and STDs</i> , 2007, 21, 609-620.	2.5	9
283	Lopinavir/Ritonavir Pharmacokinetics in HIV and Hepatitis C Virus Co-Infected Patients without Liver Function Impairment. <i>Clinical Pharmacokinetics</i> , 2007, 46, 85-92.	3.5	19
284	Genetic and catalytic efficiency structure of an HCV protease quasispecies. <i>Hepatology</i> , 2007, 45, 899-910.	7.3	33
285	Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug resistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. <i>Lancet, The</i> , 2006, 368, 466-475.	13.7	326
286	Concomitant Use of an Active Boosted Protease Inhibitor with Enfuvirtide in Treatment-Experienced, HIV-Infected Individuals: Recent Data and Consensus Recommendations. <i>HIV Clinical Trials</i> , 2006, 7, 86-96.	2.0	22
287	Genetic evolution of gp41 reveals a highly exclusive relationship between codons 36, 38 and 43 in gp41 under long-term enfuvirtide-containing salvage regimen. <i>Aids</i> , 2006, 20, 2075-2080.	2.2	41
288	Viral failure in HIV-infected patients with long-lasting viral suppression who discontinued enfuvirtide. <i>Aids</i> , 2006, 20, 1896-1898.	2.2	4

#	ARTICLE	IF	CITATIONS
289	Inhibition of human immunodeficiency virus type 1 infection in macrophages by an alpha-v integrin blocking antibody. <i>Antiviral Research</i> , 2006, 69, 173-180.	4.1	27
290	High prevalence of human papillomavirus infection in the anus, penis and mouth in HIV-positive men. <i>Aids</i> , 2006, 20, 1201-1204.	2.2	63
291	Constraints on HIV-1 evolution and immunodominance revealed in monozygotic adult twins infected with the same virus. <i>Journal of Experimental Medicine</i> , 2006, 203, 529-539.	8.5	81
292	Sequence Homology Required by Human Immunodeficiency Virus Type 1 To Escape from Short Interfering RNAs. <i>Journal of Virology</i> , 2006, 80, 571-577.	3.4	81
293	Benefits and concerns of simplification strategies in HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 58, 235-242.	3.0	35
294	Purifying selection of CCR5-tropic human immunodeficiency virus type 1 variants in AIDS subjects that have developed syncytium-inducing, CXCR4-tropic viruses. <i>Journal of General Virology</i> , 2006, 87, 1285-1294.	2.9	13
295	Longitudinal Study on Mitochondrial Effects of Didanosine+Tenofovir Combination. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 33-39.	1.1	26
296	Long-Term Safety and Efficacy of Nevirapine-Based Approaches in HIV Type 1-Infected Patients. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 321-329.	1.1	48
297	Inhibition of HIV-1 replication by RNA interference of p53 expression. <i>Journal of Leukocyte Biology</i> , 2006, 80, 659-667.	3.3	21
298	Results of a Study of Prolonging Treatment with Pegylated Interferon- α 2A plus Ribavirin in HIV/HCV-Coinfected Patients with No Early Virological Response. <i>Antiviral Therapy</i> , 2006, 11, 473-482.	1.0	21
299	$3'$ -Azido- $2'$, $3'$ -Dideoxythymidine (Zidovudine) Uptake Mechanisms in T Lymphocytes. <i>Antiviral Therapy</i> , 2006, 11, 803-812.	1.0	18
300	Increased Antiretroviral Potency by the Addition of Enfuvirtide to a Four-Drug Regimen in Antiretroviral-Naive, HIV-Infected Patients. <i>Antiviral Therapy</i> , 2006, 11, 47-51.	1.0	26
301	Antiretroviral Treatment Simplification With 3 NRTIs or 2 NRTIs Plus Nevirapine in HIV-1-Infected Patients Treated With Successful First-Line HAART. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2005, 39, 313-316.	2.1	18
302	Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine. <i>Aids</i> , 2005, 19, 569-575.	2.2	75
303	The anti-HIV activity of ADS-J1 targets the HIV-1 gp120. <i>Virology</i> , 2005, 343, 141-149.	2.4	45
304	Compromised Immunologic Recovery in Treatment-Experienced Patients with HIV Infection Receiving Both Tenofovir Disoproxil Fumarate and Didanosine in the TORO Studies. <i>Clinical Infectious Diseases</i> , 2005, 41, 901-905.	5.8	25
305	Evidence for Preferential Genotyping of a Minority Human Immunodeficiency Virus Population Due to Primer-Template Mismatching during PCR-Based Amplification. <i>Journal of Clinical Microbiology</i> , 2005, 43, 436-438.	3.9	3
306	Multiparametric Assay To Screen and Dissect the Mode of Action of Anti-Human Immunodeficiency Virus Envelope Drugs. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 3926-3929.	3.2	10

#	ARTICLE	IF	CITATIONS
307	Role of viral kinetics under HCV therapy in HIV/HCV-coinfected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 55, 824-827.	3.0	7
308	HIV Type 1 Fitness Evolution in Antiretroviral-Experienced Patients with Sustained CD4+ T Cell Counts but Persistent Virologic Failure. <i>Clinical Infectious Diseases</i> , 2005, 41, 729-737.	5.8	22
309	Phenotypic Hypersusceptibility to Multiple Protease Inhibitors and Low Replicative Capacity in Patients Who Are Chronically Infected with Human Immunodeficiency Virus Type 1. <i>Journal of Virology</i> , 2005, 79, 5907-5913.	3.4	14
310	Inhibition of Coreceptor-Independent Cell-to-Cell Human Immunodeficiency Virus Type 1 Transmission by a CD4-Immunoglobulin G2 Fusion Protein. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 4296-4304.	3.2	22
311	Analysis of Chemokine and Cytokine Expression in Patients with HIV and GB Virus Type C Coinfection. <i>Clinical Infectious Diseases</i> , 2005, 40, 1342-1349.	5.8	7
312	Measurement of Intracellular Didanosine and Tenofovir Phosphorylated Metabolites and Possible Interaction of the Two Drugs in Human Immunodeficiency Virus-Infected Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 1907-1914.	3.2	101
313	Safety of Enfuvirtide in Combination With an Optimized Background of Antiretrovirals in Treatment-Experienced HIV-1-Infected Adults Over 48 Weeks. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 40, 413-421.	2.1	83
314	Lopinavir/Ritonavir Plus Nevirapine as a Nucleoside-Sparing Approach in Antiretroviral-Experienced Patients (NEKA Study). <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 38, 47-52.	2.1	45
315	Is there evidence for an increase in the death rate from liver-related disease in patients with HIV?. <i>Aids</i> , 2005, 19, 2117-2125.	2.2	109
316	Durable Efficacy of Enfuvirtide Over 48 Weeks in Heavily Treatment-Experienced HIV-1-Infected Patients in the T-20 Versus Optimized Background Regimen Only 1 and 2 Clinical Trials. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 40, 404-412.	2.1	151
317	Evaluation of the anti-HIV activity of statins. <i>Aids</i> , 2005, 19, 1697-1700.	2.2	53
318	Reversal of HIV-1-associated osteoporosis with once-weekly alendronate. <i>Aids</i> , 2005, 19, 343-5.	2.2	45
319	Simplification Therapy with Once-Daily Didanosine, Tenofovir and Efavirenz in HIV-1-Infected Adults with Viral Suppression Receiving a More Complex Antiretroviral Regimen: Final Results of the EFADITE Trial. <i>Antiviral Therapy</i> , 2005, 10, 825-832.	1.0	17
320	Influence of Prior Structured Treatment Interruptions on the Length of Time without Antiretroviral Treatment in Chronically HIV-Infected Subjects. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 1283-1288.	1.1	15
321	Advanced Liver Fibrosis in HIV/HCV-Coinfected Patients on Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 1293-1297.	1.1	44
322	Lack of Evidence for Protease Evolution in HIV-1-Infected Patients after 2 Years of Successful Highly Active Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2004, 189, 1444-1451.	4.0	23
323	Lack of Longitudinal Inpatient Correlation between p24 Antigenemia and Levels of Human Immunodeficiency Virus (HIV) Type 1 RNA in Patients with Chronic HIV Infection during Structured Treatment Interruptions. <i>Journal of Clinical Microbiology</i> , 2004, 42, 1620-1625.	3.9	26
324	R5 HIV gp120-mediated cellular contacts induce the death of single CCR5-expressing CD4 T cells by a gp41-dependent mechanism. <i>Journal of Leukocyte Biology</i> , 2004, 76, 804-811.	3.3	51

#	ARTICLE	IF	CITATIONS
325	Genetic Screen for Monitoring Severe Acute Respiratory Syndrome Coronavirus 3C-Like Protease. <i>Journal of Virology</i> , 2004, 78, 14057-14061.	3.4	17
326	Early HCV dynamics on Peg-interferon and ribavirin in HIV/HCV co-infection. <i>Aids</i> , 2004, 18, 59-66.	2.2	43
327	Immunological and virological study of enfuvirtide-treated HIV-positive patients. <i>Aids</i> , 2004, 18, 1673-1682.	2.2	31
328	High Level of Coreceptor-independent HIV Transfer Induced by Contacts between Primary CD4 T Cells. <i>Journal of Biological Chemistry</i> , 2004, 279, 51305-51314.	3.4	89
329	Relative replication fitness of multi-nucleoside analogue-resistant HIV-1 strains bearing a dipeptide insertion in the fingers subdomain of the reverse transcriptase and mutations at codons 67 and 215. <i>Virology</i> , 2004, 326, 103-112.	2.4	35
330	Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide. <i>Aids</i> , 2004, 18, 1137-1146.	2.2	64
331	Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load. <i>Aids</i> , 2004, 18, 459-463.	2.2	103
332	Efavirenz induces a striking and generalized increase of HDL-cholesterol in HIV-infected patients. <i>Aids</i> , 2004, 18, 819-821.	2.2	46
333	Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach. <i>Antiviral Therapy</i> , 2004, 9, 335-42.	1.0	11
334	Update of the drug resistance mutations in HIV-1: 2004. <i>Topics in HIV Medicine: A Publication of the International AIDS Society, USA</i> , 2004, 12, 119-24.	2.9	27
335	Strategies for overcoming resistance in HIV-1 infected patients receiving HAART. <i>AIDS Reviews</i> , 2004, 6, 123-30.	1.0	17
336	Safety and Efficacy of Once-Daily Didanosine, Tenofovir and Nevirapine as a Simplification Antiretroviral Approach. <i>Antiviral Therapy</i> , 2004, 9, 335-342.	1.0	45
337	Clinically Validated Genotype Analysis: Guiding Principles and Statistical Concerns. <i>Antiviral Therapy</i> , 2004, 9, 465-478.	1.0	58
338	Baseline Resistance and Virological Outcome in Patients with Virological Failure who Start a Regimen Containing Abacavir: EuroSIDA Study. <i>Antiviral Therapy</i> , 2004, 9, 787-800.	1.0	7
339	Alternation of Antiretroviral Drug Regimens for HIV Infection. Efficacy, Safety and Tolerability at Week 96 of the Swatch Study. <i>Antiviral Therapy</i> , 2004, 9, 889-893.	1.0	9
340	Mitochondrial Effects of a 24-Week Course of Pegylated-Interferon plus Ribavirin in Asymptomatic HCV/HIV Co-Infected Patients on Long-Term Treatment with Didanosine, Stavudine or Both. <i>Antiviral Therapy</i> , 2004, 9, 969-977.	1.0	1
341	Cell-Surface-Expressed HIV-1 Envelope Induces the Death of CD4 T Cells during GP41-Mediated Hemifusion-like Events. <i>Virology</i> , 2003, 305, 318-329.	2.4	70
342	HIV-1 resistance to the gp41-dependent fusion inhibitor C-34. <i>Antiviral Research</i> , 2003, 59, 137-142.	4.1	63

#	ARTICLE	IF	CITATIONS
343	Antiretroviral Drug Resistance Testing in Adults Infected with Human Immunodeficiency Virus Type 1: 2003 Recommendations of an International AIDS Societyâ€‘USA Panel. <i>Clinical Infectious Diseases</i> , 2003, 37, 113-128.	5.8	495
344	Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia. <i>New England Journal of Medicine</i> , 2003, 348, 2186-2195.	27.0	676
345	Genetic Screen for Monitoring Hepatitis C Virus NS3 Serine Protease Activity. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 1760-1765.	3.2	18
346	A novel TaqMan real-time PCR assay to estimate ex vivo human immunodeficiency virus type 1 fitness in the era of multi-target (pol and env) antiretroviral therapy. <i>Journal of General Virology</i> , 2003, 84, 2217-2228.	2.9	37
347	Interleukin-7-Dependent Production of RANTES That Correlates with Human Immunodeficiency Virus Disease Progression. <i>Journal of Virology</i> , 2003, 77, 4389-4395.	3.4	23
348	Enfuvirtide (Tâ€‘20) Crossâ€‘Reactive Glycoprotein 41 Antibody Does Not Impair the Efficacy or Safety of Enfuvirtide. <i>Journal of Infectious Diseases</i> , 2003, 188, 1827-1833.	4.0	34
349	New antiretroviral drugs and approaches to HIV treatment. <i>Aids</i> , 2003, 17, S85-S96.	2.2	3
350	Virological rebound after suppression on highly active antiretroviral therapy. <i>Aids</i> , 2003, 17, 1741-1751.	2.2	99
351	A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. <i>Aids</i> , 2003, 17, 987-999.	2.2	151
352	Impact of Nevirapine on Lipid Metabolism. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003, 34, S79-S84.	2.1	50
353	Anti-HIV-1 Activity of Enfuvirtide (T-20) by Inhibition of Bystander Cell Death. <i>Antiviral Therapy</i> , 2003, 8, 155-161.	1.0	25
354	Changes in Viral Load in People with Virological Failure who Remain on the Same Haart Regimen. <i>Antiviral Therapy</i> , 2003, 8, 127-136.	1.0	24
355	Reduced Fitness of HIV-1 Resistant to Cxcr4 Antagonists. <i>Antiviral Therapy</i> , 2003, 8, 1-8.	1.0	51
356	Preferential Attachment of HIV Particles to Activated and CD45RO+CD4+T Cells. <i>AIDS Research and Human Retroviruses</i> , 2002, 18, 27-38.	1.1	12
357	Viral Dynamics during Structured Treatment Interruptions of Chronic Human Immunodeficiency Virus Type 1 Infection. <i>Journal of Virology</i> , 2002, 76, 968-979.	3.4	52
358	Virological, Immunological, and Clinical Impact of Switching from Protease Inhibitors to Nevirapine or to Efavirenz in Patients with Human Immunodeficiency Virus Infection and Long-Lasting Viral Suppression. <i>Clinical Infectious Diseases</i> , 2002, 34, 504-510.	5.8	170
359	Viral Evolution during Structured Treatment Interruptions in Chronically Human Immunodeficiency Virus-Infected Individuals. <i>Journal of Virology</i> , 2002, 76, 12344-12348.	3.4	26
360	Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions. <i>Aids</i> , 2002, 16, 895-899.	2.2	85

#	ARTICLE	IF	CITATIONS
361	Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity. <i>Aids</i> , 2002, 16, 1009-1017.	2.2	92
362	Rate of Virological Treatment Failure and Frequencies of Drug Resistance Genotypes among Human Immunodeficiency Virus-Positive Subjects on Antiretroviral Therapy in Spain. <i>Journal of Clinical Microbiology</i> , 2002, 40, 3865-3866.	3.9	30
363	Insertions in the Reverse Transcriptase Increase both Drug Resistance and Viral Fitness in a Human Immunodeficiency Virus Type 1 Isolate Harboring the Multi-Nucleoside Reverse Transcriptase Inhibitor Resistance 69 Insertion Complex Mutation. <i>Journal of Virology</i> , 2002, 76, 10546-10552.	3.4	40
364	Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. <i>Aids</i> , 2002, 16, 209-218.	2.2	267
365	Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine. <i>Aids</i> , 2002, 16, 1383-1389.	2.2	92
366	Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication. <i>Aids</i> , 2002, 16, 2385-2390.	2.2	197
367	RNA interference of HIV replication. <i>Trends in Immunology</i> , 2002, 23, 559-561.	6.8	75
368	Anti-HIV activity of a novel aminoglycoside-arginine conjugate. <i>Antiviral Research</i> , 2002, 53, 1-8.	4.1	31
369	Catalytic Efficiency and Phenotype of HIV-1 Proteases Encoding Single Critical Resistance Substitutions. <i>Virology</i> , 2002, 300, 71-78.	2.4	15
370	M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine. <i>Aids</i> , 2002, 16, 1686-1689.	2.2	44
371	Interleukin-7 in Plasma Correlates with CD4 T-Cell Depletion and May Be Associated with Emergence of Syncytium-Inducing Variants in Human Immunodeficiency Virus Type 1-Positive Individuals. <i>Journal of Virology</i> , 2001, 75, 10319-10325.	3.4	127
372	Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. <i>Aids</i> , 2001, 15, 2407-2414.	2.2	212
373	Antiretroviral Treatment Simplification With Nevirapine in Protease Inhibitor-Experienced Patients With HIV-Associated Lipodystrophy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2001, 27, 229-236.	2.1	63
374	HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection. <i>Aids</i> , 2001, 15, F19-F27.	2.2	135
375	Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients. <i>Aids</i> , 2001, 15, 2385-2395.	2.2	61
376	Clinical outcome among HIV-infected patients starting saquinavir hard gel compared to zidovudine or didanosine. <i>Aids</i> , 2001, 15, 999-1008.	2.2	8
377	Antiretroviral Treatment Simplification With Nevirapine in Protease Inhibitor-Experienced Patients With HIV-Associated Lipodystrophy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2001, 27, 229-236.	2.1	143
378	Primary HIV-1 drug resistance in Spain before and after the introduction of protease inhibitors. <i>Journal of Medical Virology</i> , 2001, 63, 85-87.	5.0	17

#	ARTICLE	IF	CITATIONS
379	Absence of Genetic Diversity Reduction in the HIV-1 Integrated Proviral LTR Sequence Population during Successful Combination Therapy. <i>Virology</i> , 2001, 282, 1-5.	2.4	9
380	CD4+ and CD8+ T Cell Death during Human Immunodeficiency Virus Infection in Vitro. <i>Virology</i> , 2001, 285, 356-365.	2.4	19
381	Stromal-cell-derived factor 1 prevents the emergence of the syncytium-inducing phenotype of HIV-1 in vivo. <i>Aids</i> , 2001, 15, 1890-1892.	2.2	15
382	Changes in the rate of genotypic resistance to antiretroviral drugs in Spain. <i>Aids</i> , 2001, 15, 1894-1896.	2.2	37
383	Psychological impact of structured treatment interruptions in patients with prolonged undetectable HIV-1 viral loads. <i>Aids</i> , 2001, 15, 1904-1906.	2.2	19
384	The CXCR4 Antagonist AMD3100 Efficiently Inhibits Cell-Surface-Expressed Human Immunodeficiency Virus Type 1 Envelope-Induced Apoptosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 51-56.	3.2	59
385	Prevalence and Characteristics of Multinucleoside-Resistant Human Immunodeficiency Virus Type 1 among European Patients Receiving Combinations of Nucleoside Analogues. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 2109-2117.	3.2	101
386	Anti-Human Immunodeficiency Virus Activity of Novel Aminoglycoside-Arginine Conjugates at Early Stages of Infection. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 627-634.	1.1	36
387	Prospective Randomized Two-Arm Controlled Study To Determine the Efficacy of a Specific Intervention To Improve Long-Term Adherence to Highly Active Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2000, 25, 221-228.	2.1	203
388	Prospective Randomized Two-Arm Controlled Study To Determine the Efficacy of a Specific Intervention To Improve Long-Term Adherence to Highly Active Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2000, , 221-228.	2.1	42
389	Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain. <i>Aids</i> , 2000, 14, 727-732.	2.2	53
390	The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: results from a randomized, double-blind, trial. <i>Aids</i> , 2000, 14, 781-789.	2.2	49
391	Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression. <i>Aids</i> , 2000, 14, 397-403.	2.2	189
392	Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection. <i>JAMA - Journal of the American Medical Association</i> , 2000, 283, 2417.	7.4	647
393	A Bacteriophage Lambda-Based Genetic Screen for Characterization of the Activity and Phenotype of the Human Immunodeficiency Virus Type 1 Protease. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 1132-1139.	3.2	27
394	Patient HIV-1 strains carrying the multiple nucleoside resistance mutations are cross-resistant to abacavir. <i>Aids</i> , 2000, 14, 469.	2.2	28
395	Human immunodeficiency virus type 1 population bottleneck during indinavir therapy causes a genetic drift in the env quasispecies. <i>Microbiology (United Kingdom)</i> , 2000, 81, 85-95.	1.8	23
396	The implication of the chemokine receptor CXCR4 in HIV-1 envelope protein-induced apoptosis is independent of the G protein-mediated signalling. <i>Aids</i> , 1999, 13, 909-917.	2.2	74

#	ARTICLE	IF	CITATIONS
397	Quantification of integrated and total HIV-1 DNA after long-term highly active antiretroviral therapy in HIV-1-infected patients. <i>Aids</i> , 1999, 13, 1045-1049.	2.2	80
398	Activity of Different Bicyclam Derivatives against Human Immunodeficiency Virus Depends on Their Interaction with the CXCR4 Chemokine Receptor. <i>Molecular Pharmacology</i> , 1999, 55, 67-73.	2.3	107
399	Efficacy of Low-Dose Subcutaneous Interleukin-2 to Treat Advanced Human Immunodeficiency Virus Type 1 in Persons with $\geq 1/2250/1/4L$ CD4 T Cells and Undetectable Plasma Virus Load. <i>Journal of Infectious Diseases</i> , 1999, 180, 56-60.	4.0	110
400	Resistance of the Human Immunodeficiency Virus to the Inhibitory Action of Negatively Charged Albumins on Virus Binding to CD4. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 1535-1543.	1.1	22
401	Human Immunodeficiency Virus Type 1 Genetic Evolution in Patients with Prolonged Suppression of Plasma Viremia. <i>Virology</i> , 1999, 256, 180-187.	2.4	60
402	Chemokine and chemokine receptor expression after combined anti-HIV-1 interleukin-2 therapy. <i>Aids</i> , 1999, 13, 547-555.	2.2	25
403	Protease inhibitor-containing regimens compared with nucleoside analogues alone in the suppression of persistent HIV-1 replication in lymphoid tissue. <i>Aids</i> , 1999, 13, F1-F8.	2.2	81
404	Shift of Clinical Human Immunodeficiency Virus Type 1 Isolates from X4 to R5 and Prevention of Emergence of the Syncytium-Inducing Phenotype by Blockade of CXCR4. <i>Journal of Virology</i> , 1999, 73, 5577-5585.	3.4	90
405	Comparison of the LiPA HIV-1 RT test, selective PCR and direct solid phase sequencing for the detection of HIV-1 drug resistance mutations. <i>Journal of Virological Methods</i> , 1998, 73, 77-82.	2.1	34
406	Prevalence and genotypes of GB virus C/hepatitis G virus (GBV-C/HGV) and hepatitis C virus among patients infected with human immunodeficiency virus: Evidence of GBV-C/HGV sexual transmission. , 1998, 55, 293-299.		38
407	Antiretroviral Drug Resistance Testing in Adults With HIV Infection. <i>JAMA - Journal of the American Medical Association</i> , 1998, 279, 1984.	7.4	528
408	Human Immunodeficiency Virus Glycoprotein gp120 as the Primary Target for the Antiviral Action of AR177 (Zintevir). <i>Molecular Pharmacology</i> , 1998, 53, 340-345.	2.3	118
409	Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain. <i>Aids</i> , 1998, 12, 1015-1020.	2.2	118
410	Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries. <i>Aids</i> , 1998, 12, 2007-2015.	2.2	77
411	Impact on the immune system of undetectable plasma HIV-1 RNA for more than 2 years. <i>Aids</i> , 1998, 12, 697-704.	2.2	37